eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Recenzenci Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
2/2021
vol. 37
 
Poleć ten artykuł:
Udostępnij:
Artykuł oryginalny

Występowanie zakażenia COVID-19 u 50 pacjentów otrzymujących lit

Janusz Rybakowski
1

  1. Poznan University of Medical Sciences, Department of Adult Psychiatry
Farmakoterapia w Psychiatrii i Neurologii 2021, 37 (2), 113–121
Data publikacji online: 2021/12/07
Plik artykułu:
Pobierz cytowanie
 
Metryki PlumX:
 
1. Amsterdam JD, García-España F, Rybakowski J. Rates of flulike infection in patients with affective illness. J Affect Disord 1998; 47: 177-182.
2. Dotson S, Hartvigsen N, Wesner T, Carbary TJ, Fricchione G, Freudenreich O. Clozapine toxicity in the setting of COVID-19. Psychosomatics. 2020; 61: 577-578.
3. Gattner K, Rybakowski J. A severe course of the COVID-19 in a patient receiving prophylactically lithium. Pharmacother Psychiatry Neurol 2020; 36: 143-148.
4. Lieb J. Remission of recurrent herpes infection during therapy with lithium. N Eng J Med 1979; 301: 942.
5. Llesuy JR, Sidelnik SA. Death from COVID-19 in a patient receiving clozapine: Factors involved and prevention strategies to consider. Prim Care Companion CNS Disord. 2020; 22: 20l02699.
6. Murru A, Manchia M, Hajek T, Nielsen RE, Rybakowski JK, Sani G et al. Lithium’s antiviral effects: a potential drug for COVID-19 disease? Int J Bipolar Disord. 2020; 8: 21.
7. Nowak JK, Walkowiak J. Lithium and coronavirus infections. A scoping review. F1000Research 2020; 9: 93.
8. Qaswal AB, Guzu H, Suleiman A, Atiyat B. The potential role of lithium as an antiviral agent against SARS-CoV-2 via membrane depolarization: review and hypothesis. Sci Pharm 2021; 89; 11.
9. Rajkumar RP. Lithium as a candidate treatment for COVID-19: Promises and pitfalls. Drug Dev Res. 2020; 81: 782-785.
10. Rudd CE. Commentary: Does lithium deserve a place in the treatment against COVID-19? A preliminary observational study in six patients, case report. Front Pharmacol. 2020a; 11: 613734.
11. Rudd CE. GSK-3 inhibition as a therapeutic approach against SARs CoV2: Dual benefit of inhibiting viral replication while potentiating the immune response. Front Immunol 2020b; 11: 1638.
12. Rybakowski J. Informacja dotycząca stosowania litu w okresie pandemii COVID-19. Psychiatra 2020; 28: 48-49.
13. Rybakowski JK, Amsterdam JD. Lithium prophylaxis and recurrent labial herpes infections. Lithium 1991; 2: 43-47.
14. Rybakowski JK, Suwalska A, Hajek T. Clinical perspectives of lithium’s neuroprotective effect. Pharmacopsychiatry 2018; 51: 194-199.
15. Rybakowski JK. Antiviral and immunomodulatory effect of lithium. Pharmacopsychiatry 2000; 33: 159-164. 16. Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord 2014; 2: 15.
16. Skinner GRB, Hartley C, Buchan A, Harper L, Gallimore P. The effect of lithium chloride on the replication of herpes simplex virus. Med Microbiol Immunol 1980; 168: 258-265.
17. Smith KA, Cipriani A. Lithium and suicide in mood disorders: Updated meta-review of the scientific literature. Bipolar Disorders 2017; 19: 575-586.
18. Spuch C, López-García M, Rivera-Baltanás T, Rodrígues- Amorím D, Olivares JM. Does lithium deserve a place in the treatment against COVID-19? A preliminary observational study in six patients, case report. Front Pharmacol. 2020; 11: 557629.
19. Suwanwongse K, Shabarek N. Lithium toxicity in two coronavirus disease 2019 (COVID-19) patients. Cureus. 2020; 12: e8384

© 2024 Termedia Sp. z o.o.
Developed by Bentus.